Modality
Cell Therapy
MOA
WRNi
Target
MALT1
Pathway
Hedgehog
OCD
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
~Nov 2018
→ ~Feb 2020
Phase 3
May 2020
→ Apr 2028
Phase 3Current
NCT04788411
1,693 pts·OCD
2020-05→2028-04·Terminated
NCT05945848
2,500 pts·OCD
2021-12→2028-02·Terminated
4,193 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-02-021.8y awayPh3 Readout· OCD
2028-04-192.1y awayPh3 Readout· OCD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2028-02-02 · 1.8y away
OCD
Ph3 Readout
2028-04-19 · 2.1y away
OCD
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04788411 | Phase 3 | OCD | Terminated | 1693 | PANSS |
| NCT05945848 | Phase 3 | OCD | Terminated | 2500 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |